Please Wait
Applying Filters...
menu
    • menu
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Oct 2024: Lundbeck acquires Longboard for US$ 2.6 bn; molecular glue degrader tech witnesses dealmaking

    Stock Recap
    #PipelineProspector

    Menu

    CB-5339

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    28/10/2024 Cleave Therapeutics
    U.S.A
    		 CASI PHARMACEUTICALS INC 34023 CB-5339 DRUG PRODUCT 2019-09-06 Active II N/A
    28/10/2024 Cleave Therapeutics
    U.S.A
    		 CASI PHARMACEUTICALS INC 34034 CB 5339 DRUG SUBSTANCE 2019-09-06 Active II N/A